Lapatinib for the treatment of breast cancer in the People’s Republic of China

Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor–2 (HER2) tyrosine kinases. In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine for the treatment o...

Descripción completa

Detalles Bibliográficos
Autor principal: Wang, Hongjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125370/
https://www.ncbi.nlm.nih.gov/pubmed/25114575
http://dx.doi.org/10.2147/OTT.S60586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125370/
https://www.ncbi.nlm.nih.gov/pubmed/25114575
http://dx.doi.org/10.2147/OTT.S60586

Ejemplares similares